Analyst Price Targets — IBRX
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| May 8, 2026 11:24 am | — | BTIG | $12.00 | $7.76 | TheFly | ImmunityBio price target lowered to $12 from $13 at BTIG |
| March 4, 2026 12:54 pm | Edward Tenthoff | Piper Sandler | $12.00 | $9.20 | StreetInsider | Immunitybio Inc (IBRX) PT Raised to $12 at Piper Sandler |
| February 23, 2026 5:43 pm | — | H.C. Wainwright | $15.00 | $9.71 | TheFly | ImmunityBio price target raised to $15 from $10 at H.C. Wainwright |
| January 20, 2026 11:49 am | — | Piper Sandler | $7.00 | $5.52 | TheFly | ImmunityBio price target raised to $7 from $5 at Piper Sandler |
| January 10, 2025 11:49 am | Justin Zelin | BTIG | $6.00 | $2.42 | TheFly | ImmunityBio initiated with a Buy at BTIG |
| August 3, 2022 9:24 am | Kelly Shi | Jefferies | $8.00 | $4.13 | TheFly | Jefferies starts ImmunityBio at Buy on Anktiva potential, IO pipeline |
Latest News for IBRX
ImmunityBio, Inc. (IBRX) Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - Contact Kessler Topaz Meltzer and Check
Did you buy CAPR securities between December 17, 2025 and July 26, 2026? Affected CAPR Investor Summary Who: Capricor Therapeutics, Inc. (NASDAQ: CAPR) What: Securities fraud class action lawsuit filed Class Period: December 17, 2025 through July 26, 2026 Deadline to Seek Lead Plaintiff Status: September 28, 2026 Key Lawsuit Allegations: Material misstatements and/or omissions concerning the company's lead product…
Bell and Brown Wealth Advisors LLC purchased a new stake in ImmunityBio, Inc. (NASDAQ: IBRX) in the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 75,050 shares of the company's stock, valued at approximately $657,000. A number of other large investors have also
Bank of America Corp DE grew its stake in shares of ImmunityBio, Inc. (NASDAQ: IBRX) by 2.7% in the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 2,447,843 shares of the company's stock after purchasing an additional 65,340 shares during the quarter. Bank of
CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), a commercial-stage immunotherapy company, today announced that Dr. Jim Yong Kim has joined the company as Vice Chairman. Dr. Kim will serve in a newly created Office of the Executive Chairman, where he will focus on strengthening the company's international and global relationships. He will report to Executive Chairman and Founder Dr. Patrick…
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for IBRX.
U.S. House Trading
House Trades Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.